Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bartlett who wrote (1661)	4/17/1999 1:55:00 PM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

Mark, I'm sure I heard that the FDA had come up earlier and I thought I'd read it on this thread that Peter said Dimethaid had answered those questions (five or six months ago)? I don't know the exact blend of criteria the FDA will use, but, I've got to believe study size has been long looked at and is one of those continue/stop points early in the process. Why visit the manufacturing site? Because the size of the Pennsaid studies is not at issue with the FDA. My opinion. I've heard enough to believe we're at the point of arranging with the HPB for the FDA to visit the site - not talking sample size. However, I agree Dimethaid has been weak in getting attention in an acceptable way. Look at the human interest story they got in. She's playing the piano again! Brilliant! Not worried though. This market is SO big.